Xiaobo Li
2 Papers
Xiaobo Li is an academic researcher. The author has contributed to research in topics: Proinflammatory cytokine & Virus. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.
Qinhai Ma,Weiqi Pan,Run-Feng Li,Bin Liu,Chufang Li,Yuqi Xie,Zhoulang Wang,Jin Zhao,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Zifeng Yang +14 more
TL;DR: Findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.
118
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Qinhai Ma,Runfeng Li,Weiqi Pan,Wenbo Huang,Bin Liu,Yuqi Xie,Zhoulang Wang,Chufang Li,Haiming Jiang,Jicheng Huang,Yongxia Shi,Jun Dai,Kui Zheng,Xiaobo Li,Min Hui,Li Fu,Zifeng Yang,Zifeng Yang +17 more
TL;DR: Investigation of the antiviral and anti-inflammatory activities of KD-1 against the novel SARS-CoV-2 and H coV-229E indicated that KD- 1 protected against virus and can thus be used as a novel strategy for controlling coronavirus 2019.